Michel Detheux, Chief Executive Officer at iTeos Therapeutics, Inc. (ITOS), sold 288,494 shares at $10.10 ($2.9M) on 2025-06-04, disclosed to the SEC on 2025-06-06.
Scheduled sale ($2.9M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.10 | 8,400 | $85K | 2.9% |
| 2 | $10.10 | 43,883 | $443K | 15.1% |
| 3 | $10.10 | 43,883 | $443K | 15.1% |
| 4 | $10.15 | 8,400 | $85K | 2.9% |
| 5 | $10.15 | 43,882 | $445K | 15.2% |
| 6 | $10.15 | 43,882 |
| $445K |
| 15.2% |
| 7 | $10.21 | 8,400 | $86K | 2.9% |
| 8 | $10.21 | 43,882 | $448K | 15.3% |
| 9 | $10.21 | 43,882 | $448K | 15.3% |
| Total | $10.15 avg | 288,494 | $2.9M | 100% |
| Filing → |
| ITOS | SELL | 2022-03-22 | $1.2M | — | Filing → |
| ITOS | SELL | 2022-02-24 | $977K | — | Filing → |
| ITOS | SELL | 2022-01-26 | $1.0M | — | Filing → |